Literature DB >> 12642309

Five year risk of progression of primary angle closure suspects to primary angle closure: a population based study.

R Thomas1, R George, R Parikh, J Muliyil, A Jacob.   

Abstract

AIM: To report progression of primary angle closure suspects (PACS) to primary angle closure (PAC) at the 5 year follow up of a population based sample.
METHODS: 82 of 118 PACS who could be contacted and 110 randomly selected normals from a population based survey in 1995 were invited for a follow up examination in 2000. Progression to PAC was based on the development of raised IOP or synechiae in a PACS.
RESULTS: 50 of the 82 PACS contacted were examined. 11 (22%; 95% CI 9.8 to 34.2) developed PAC (seven synechial and four appositional); all were bilateral PACS. Two of 50 people previously diagnosed as PACS were reclassified as normal. One person among the 110 normals progressed to PAC. The relative risk of progression among PACS was 24 (95% CI 3.2 to 182.4). There was no significant difference in axial length, anterior chamber depth, or lens thickness between those who progressed and those who did not. None of the patients developed optic disc or field damage attributable to angle closure. One angle closure suspect was diagnosed to have normotensive glaucoma.
CONCLUSION: In this population based study of PACS the 5 year incidence of PAC was 22%; none developed functional damage. Bilateral PACS was a clinical risk factor for progression.

Entities:  

Mesh:

Year:  2003        PMID: 12642309      PMCID: PMC1771602          DOI: 10.1136/bjo.87.4.450

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  Detection of gonioscopically occludable angles and primary angle closure glaucoma by estimation of limbal chamber depth in Asians: modified grading scheme.

Authors:  P J Foster; J G Devereux; P H Alsbirk; P S Lee; D Uranchimeg; D Machin; G J Johnson; J Baasanhu
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 2.  Gonioscopy.

Authors:  R Thomas; S Thomas; G Chandrashekar
Journal:  Indian J Ophthalmol       Date:  1998-12       Impact factor: 1.848

3.  Who needs an iridotomy?

Authors:  D S Friedman
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

4.  Glaucoma in southern India.

Authors:  R Thomas; J Muliyil; R George
Journal:  Ophthalmology       Date:  2001-07       Impact factor: 12.079

Review 5.  Number of people with glaucoma worldwide.

Authors:  H A Quigley
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

6.  Increase in iris-lens contact after laser iridotomy for pupillary block angle closure.

Authors:  R M Caronia; J M Liebmann; Z Stegman; J Sokol; R Ritch
Journal:  Am J Ophthalmol       Date:  1996-07       Impact factor: 5.258

7.  Outcome of laser peripheral iridotomy in chronic primary angle closure glaucoma.

Authors:  R Thomas; T Arun; J Muliyil; R George
Journal:  Ophthalmic Surg Lasers       Date:  1999 Jul-Aug

8.  The flashlight test and van Herick's test are poor predictors for occludable angles.

Authors:  R Thomas; T George; A Braganza; J Muliyil
Journal:  Aust N Z J Ophthalmol       Date:  1996-08

9.  Lens extraction for uncontrolled angle-closure glaucoma: long-term follow-up.

Authors:  F P Gunning; E L Greve
Journal:  J Cataract Refract Surg       Date:  1998-10       Impact factor: 3.351

10.  Prevalence of primary glaucoma in an urban south Indian population.

Authors:  A Jacob; R Thomas; S P Koshi; A Braganza; J Muliyil
Journal:  Indian J Ophthalmol       Date:  1998-06       Impact factor: 1.848

View more
  50 in total

1.  Ocular biometry in occludable angles and angle closure glaucoma: a population based survey.

Authors:  R George; P G Paul; M Baskaran; S Ve Ramesh; P Raju; H Arvind; C McCarty; L Vijaya
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

2.  Differences in baseline dark and the dark-to-light changes in anterior chamber angle parameters in whites and ethnic Chinese.

Authors:  Dandan Wang; Cynthia Chiu; Mingguang He; Lingling Wu; Andrew Kao; Shan Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-09       Impact factor: 4.799

3.  Anterior segment changes after pharmacologic mydriasis using Pentacam and optical coherence tomography in angle closure suspects.

Authors:  Jing-Min Guo; Mu Li; Xiao-Lan Xu; Hong Zhang; Jun-Ming Wang
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

Review 4.  The future of glaucoma clinics.

Authors:  A M S Morley; I Murdoch
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

5.  Prevention of primary angle-closure glaucoma in Asia.

Authors:  Winifred P Nolan
Journal:  Br J Ophthalmol       Date:  2007-07       Impact factor: 4.638

6.  How to manage a patient with glaucoma in Asia.

Authors:  Jennifer Ly Yip; Paul J Foster
Journal:  Community Eye Health       Date:  2006-09

7.  Qualitative assessment of ultrasound biomicroscopic images using standard photographs: the liwan eye study.

Authors:  Yuzhen Jiang; Mingguang He; Wenyong Huang; Qunxiao Huang; Jian Zhang; Paul J Foster
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

Review 8.  Gonioscopy findings and prevalence of occludable angles in a Burmese population: the Meiktila Eye Study.

Authors:  R J Casson; H S Newland; J Muecke; S McGovern; L M Abraham; W K Shein; D Selva; T Aung
Journal:  Br J Ophthalmol       Date:  2007-07       Impact factor: 4.638

9.  Low iris and anterior chamber volume is associated with deepening after laser peripheral iridotomy in primary angle closure suspects.

Authors:  Hamed Esfandiari; Mohammad Pakravan; Nassim Amouhashemi; Mehdi Yaseri; Pooya Torkian; Khosrow Jadidi; Nils A Loewen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-02       Impact factor: 3.117

10.  Non-contact tests for identifying people at risk of primary angle closure glaucoma.

Authors:  Anish Jindal; Irene Ctori; Gianni Virgili; Ersilia Lucenteforte; John G Lawrenson
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.